We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Broad-Spectrum Antiparasitic Drug Ivermectin Could Help `Cure` COVID-19

By HospiMedica International staff writers
Posted on 16 Jun 2020
Print article
Illustration
Illustration
Ivermectin, a broad-spectrum antiparasitic agent that has also been shown to fight viruses, is currently being tested in a study to evaluate its effectiveness as a treatment for COVID-19.

Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center (Tel Hashomer, Israel), has launched a clinical trial of Ivermectin and believes that the drug could help “cure” COVID-19, according to a report by The Jerusalem Post. Schwartz believes that Ivermectin could help reduce the duration of infection in COVID-19 patients and allow them to return to work and usual business in a few days.

Schwartz told The Jerusalem Post that Ivermectin is being tested in COVID-19 patients with mild to moderate symptoms to evaluate if the drug could reduce the viral shedding period, allow the patients to test negative for coronavirus and leave isolation in just a few days. Until now, 26 people have been enrolled in the randomized, parallel assignment, double-blind quadruple mask study of 100 patients. Schwartz hopes to establish viral clearance within six days post-intervention and is also monitoring whether Ivermectin can help speed up the reduction of symptoms.

Anti-parasitic drugs have earlier been in the news for their much-touted ability to kill the SARS-CoV-2 virus. A study on Ivermectin conducted by Australian researchers in April had also showed positive results. In May, a doctor from Bangladesh had claimed that Ivermectin repurposed for the treatment of COVID-19 had helped a patient to recover completely from the infection in just four days and the anti-parasitic drug could kill the SARS-CoV-2 virus in just 48 hours.

Another anti-parasitic drug niclosamide tested on ferrets in a study by Daewoong Pharmaceutical Co., Ltd. (Seoul, Korea) was found to have eliminated the novel coronavirus from their lungs. According to Daewoong, its experimental anti-viral drug completely cleared up the disease in the lung tissues of ferrets and the company now plans to start human clinical trials in July with approval of the COVID-19 treatment drug expected by the end of this year.

Related Links:
Sheba Medical Center
Daewoong Pharmaceutical Co., Ltd.


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Vein Illuminator
VSI

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.